High False-Positive Rate of (1,3)-β-D-Glucan in Onco-Hematological Patients Receiving Immunoglobulins and Therapeutic Antibodies.
Détails
ID Serval
serval:BIB_D7EA460AD1EC
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
High False-Positive Rate of (1,3)-β-D-Glucan in Onco-Hematological Patients Receiving Immunoglobulins and Therapeutic Antibodies.
Périodique
Clinical infectious diseases
ISSN
1537-6591 (Electronic)
ISSN-L
1058-4838
Statut éditorial
Publié
Date de publication
25/08/2022
Peer-reviewed
Oui
Volume
75
Numéro
2
Pages
330-333
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Publication Status: ppublish
Résumé
Immunoglobulins and/or therapeutic antibody preparations are associated with a high rate of false-positive (1,3)-β-D-glucan (BDG) tests in onco-hematological patients routinely screened for fungal infections. The benefit of BDG monitoring shall be balanced against the risk of false-positive tests leading to unnecessary investigations and costs in this population.
Mots-clé
Glucans, Humans, Immunoglobulins, Proteoglycans, Sensitivity and Specificity, beta-Glucans, false-positive, intravenous immunoglobulines, onco-hematology, therapeutic antibodies, β-D-glucan
Pubmed
Web of science
Open Access
Oui
Création de la notice
10/01/2022 9:25
Dernière modification de la notice
07/09/2022 5:39
Données d'usage
